Biological age acceleration burdens

1. Biological age acceleration burdens improve FINDRISC prediction accuracy in humans (Up to 10.9% improvement).

   “Incorporating BioAgeAccel burden into FINDRISC significantly enhanced prediction accuracy, reaching up to 10.9% improvement in some specific aging transition statuses.”

   HumansAdding biological age acceleration burden to FINDRISC; improvement varied by aging transition statusn = 13,751

   Longitudinal insights into dynamic patterns and cumulative burdens of biological age acceleration in relation to type II diabetes mellitus, all-cause mortality and glycemic traits

   medRxiv·7 Apr 2026Preprint

1. Biological age acceleration burdens are associated with mortality in humans (KDMAccel: HR 1.25 [1.07–1.47]; PhenoAgeAccel: HR 1.51 [1.31–1.74]).

   “and all-cause mortality (KDMAccel: HR=1.25 [1.07~1.47]; PhenoAgeAccel: HR=1.51 [1.31~1.74]).”

   HumansCumulative biological age acceleration burdenMedian follow-up of 9.5 yearsn = 13,751

   Longitudinal insights into dynamic patterns and cumulative burdens of biological age acceleration in relation to type II diabetes mellitus, all-cause mortality and glycemic traits

   medRxiv·7 Apr 2026Preprint

1. Biological age acceleration burdens are associated with type 2 diabetes in humans (KDMAccel: HR 1.25 [1.03–1.51]; PhenoAgeAccel: HR 1.26 [1.06–1.49]).

   “BioAgeAccel burdens demonstrated dose-response effects, with cumulative BioAgeAccel showing the greatest influence on T2D (KDMAccel: HR=1.25 [1.03~1.51]; PhenoAgeAccel: HR=1.26 [1.06~1.49])”

   HumansCumulative biological age acceleration burdenMedian follow-up of 9.5 yearsn = 13,751

   Longitudinal insights into dynamic patterns and cumulative burdens of biological age acceleration in relation to type II diabetes mellitus, all-cause mortality and glycemic traits

   medRxiv·7 Apr 2026Preprint

More on Type 2 diabetes